Unlocking the potential of bispecific ADCs for targeted cancer therapy
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a ‘magic…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Gene signature shows promise to improve survival for breast cancer patients
Using a gene signature technique to tailor chemotherapy for patients with early triple-negative breast cancer…
Treatments used for HER2-positive breast cancers could help patients with rare bile duct cancer
Drugs designed to target HER2-positive breast cancer could also benefit some patients with bile duct…
Tiny tumour model recreates cancer metastasis
Scientists have created a 3D-printed model to mimic the specific conditions that spur the spread…
New research shows urine tests may detect early diseases
Early detection is critical when it comes to curing diseases like cancer, but not everyone…
Scientists discover how excessive red meat consumption increases colorectal cancer risk
Scientists at the Agency for Science, Technology and Research (A*STAR) along with collaborators from the…
Study increases understanding of what makes multiply recurrent meningiomas a most aggressive form of brain tumour
Researchers at Baylor College of Medicine and Washington University School of Medicine in St. Louis,…
Scientists create cancer patients’ ‘digital twins’ to predict how well treatments may work
Researchers have shown that they can accurately re-create clinical trials of new treatments using ‘digital…
Researchers develop low-cost device that detects cancer in an hour
Researchers at The University of Texas at El Paso, USA, have created a portable device…
Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer
Researchers from The University of Texas MD Anderson Cancer Centre, USA, demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted…